This review concludes that body weight and age were the most important factors associated with the clearance of theophylline in paediatric patients. Body weight, age and smoking were most frequently used to estimate the clearance of theophylline in adults. Future studies are warranted to detect the influence of new factors, such as cytochrome P450 (CYP) 1A2 gene polymorphisms, on the pharmacokinetics of theophylline because some pharmacokinetic variability was not fully explained.
The
activation of the cyclic GMP-AMP synthase-stimulator of interferon
gene (STING) pathway has been associated with the pathogenesis of
many autoimmune and inflammatory disorders, and small molecules targeting
STING have emerged as a new therapeutic strategy for the treatment
of these diseases. While several STING inhibitors have been identified
with potent anti-inflammatory effects, we would like to explore STING
degraders based on the proteolysis-targeting chimera (PROTAC) technology
as an alternative strategy to target the STING pathway. Thus, we designed
and synthesized a series of STING protein degraders based on a small-molecule
STING inhibitor (C-170) and pomalidomide (a CRBN ligand).
These compounds demonstrated moderate STING-degrading activities.
Among them, SP23 achieved the highest degradation potency
with a DC50 of 3.2 μM. Importantly, SP23 exerted high anti-inflammatory efficacy in a cisplatin-induced acute
kidney injury mouse model by modulating the STING signaling pathway.
Taken together, SP23 represents the first PROTAC degrader
of STING deserving further investigation as a new anti-inflammatory
agent.
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory illness, particularly in infants, the elderly, and immunocompromised adults. There is no licensed commercial vaccine against RSV. Importantly, formalin-inactivated RSV vaccines mediate enhanced respiratory disease. RSV fusion (F) protein with pre-fusion conformation is a promising candidate subunit vaccine. However, some problems remain to be solved, such as low immunogenicity and humoral immunity bias. Adjuvants can effectively enhance and adjust vaccine immune responses. In this study, we formulated pre-fusion RSV-F protein with the adjuvants, Alhydrogel, MF59, AS03, AS02, and glycol chitosan (GCS). We then conducted head-to-head comparisons of vaccine-induced immune responses in BALB/c mice. All adjuvanted vaccines enhanced antigen-specific and neutralizing antibody titers and viral clearance and gave an order of adjuvant activity: AS02 > AS03, MF59 > GCS, and Alhydrogel. Among them, AS02 elicited the highest antibody expression, which persisted until week 18. Moreover, AS02 significantly enhanced Th1 type immune response in immunized mice. Mice in the AS02 group also showed faster recovery from viral attacks in challenge tests. Further transcriptome analysis revealed that AS02 regulates immune balance by activating TLR-4 and promotes Th1-type immune responses. These results suggest that AS02 may be an excellent candidate adjuvant for RSV-F subunit vaccines. This study also provides valuable information regarding the effect of other adjuvants on immune responses of RSV-F subunit vaccines.
BackgroundZein-based carriers are a promising delivery system for biomedical applications. However, few studies involve systematic investigation on their in vivo biocompatibility and immunogenicity.PurposeThe objective of this study was to identify the immunogenicity, type of immune response, biocompatibility and systemic recall immune response of zein nanoparticles administrated via different routes in mice.Animals and methodsFemale Balb/c mice were selected as the animal model in this paper. The effect of particle size, dose and inoculation routes on immunogenicity were systematically explored. The mice were challenged at week 50 via intramuscular and subcutaneous routes to investigate the systemic recall immune responses of zein nanoparticles. Hematoxylin and eosin staining was performed to investigate the biocompatibility of zein nanoparticles at injection sites.ResultsThe administration of zein particles by parenteral routes led to a long-term systemic immune response. Particle size did not affect zein-specific IgG antibody titers. IgG antibody titers and inflammatory cell infiltration at the injection sites resulting from intramuscular zein particle injection were significantly higher than those from subcutaneous injection of the same dose. For intramuscular inoculation, dose-dependent IgG antibody titers were observed after the third inoculation, while no significant difference was found via the subcutaneous route. For both routes, IgG titer showed a time-dependent decrease at all dose levels from week 5 onward, and finally plateaued at week 28. The IgG subtype assay showed a predominant Th2-type immune response for both administration routes. Challenge with zein nanoparticles at week 50 led to a significant increase in specific IgG titer at all dose levels, indicating systemic recall immune responses. Interestingly, IgG antibody levels in the subcutaneous groups showed a delayed decrease compared to those of the intramuscular injection groups at all dose levels.ConclusionThis study indicated that immunogenicity may be one of the key challenges of using zein nanoparticles as carriers via parenteral administration. Further investigation is needed to illustrate zein immunogenicity in other forms, and the possible effect of systemic recall immune response on in vivo pharmacokinetic characteristics.
Novel
enzyme-triggerable cell penetrating peptide (ETCPP) dendrimers
with a camptothecin (CPT) warhead were designed and synthesized based
on an amphiphilic penetrating peptide (FKKFFRKLL, discovered by us
before). Among the newly synthesized ETCPP dendrimer conjugates, BL_Oc-SS-CPT
(a high-generation dendrimer) exhibited the highest activity with
IC50s in the nanomolar range (31–747 nM) against
a panel of cancer cells, which is 3–10 times better than that
of CPT. BL_Oc-SS-CPT remained intact during transit to target cells
and in normal tissues with a plasma half-life of 4.2 h, 2.3-fold longer
than that of the monomer (1.8 h). Once reaching the tumor site, BL_Oc-SS-CPT
gradually released CPT in the presence of excessive matrix metalloproteinase-2/9
and GSH in cancer cells. Importantly, BL_Oc-SS-CPT exhibited excellent
in vivo tumor targeting capability and antitumor efficacy with benign
toxicity profiles. Thus, the novel ETCPP dendrimer-based drug delivery
system (e.g., BL_Oc-SS-CPT) represents a safe and effective strategy
for targeted cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.